Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

Stephen I. Pelton; Ron Dagan; Beverly M. Gaines; Keith P. Klugman; Dagna Laufer; Katherine O'Brien; Heinz J. Schmitt

doi:10.1016/S0264-410X(02)00681-3

Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

Stephen I. Pelton, Ron Dagan, Beverly M. Gaines, Keith P. Klugman, Dagna Laufer, Katherine O'Brien, Heinz J. Schmitt

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.

Original language	English
Pages (from-to)	1562-1571
Number of pages	10
Journal	Vaccine
Volume	21
Issue number	15
DOIs	https://doi.org/10.1016/S0264-410X(02)00681-3
State	Published - 2 Apr 2003

Keywords

Acute otitis media
Pneumococcal conjugate vaccines
Streptococcus pneumoniae

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(02)00681-3

Cite this

@article{b042ff5443d64568a78e93bf8ac67d7d,

title = "Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy",

abstract = "Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.",

keywords = "Acute otitis media, Pneumococcal conjugate vaccines, Streptococcus pneumoniae",

author = "Pelton, {Stephen I.} and Ron Dagan and Gaines, {Beverly M.} and Klugman, {Keith P.} and Dagna Laufer and Katherine O'Brien and Schmitt, {Heinz J.}",

year = "2003",

month = apr,

day = "2",

doi = "10.1016/S0264-410X(02)00681-3",

language = "English",

volume = "21",

pages = "1562--1571",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "15",

}

TY - JOUR

T1 - Pneumococcal conjugate vaccines

T2 - Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

AU - Pelton, Stephen I.

AU - Dagan, Ron

AU - Gaines, Beverly M.

AU - Klugman, Keith P.

AU - Laufer, Dagna

AU - O'Brien, Katherine

AU - Schmitt, Heinz J.

PY - 2003/4/2

Y1 - 2003/4/2

N2 - Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.

AB - Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.

KW - Acute otitis media

KW - Pneumococcal conjugate vaccines

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=0037413970&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00681-3

DO - 10.1016/S0264-410X(02)00681-3

M3 - Article

C2 - 12639477

AN - SCOPUS:0037413970

SN - 0264-410X

VL - 21

SP - 1562

EP - 1571

JO - Vaccine

JF - Vaccine

IS - 15

ER -

Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this